| | |
| Clinical data | |
|---|---|
| Trade names | Solosec |
| Other names | PM-185184; RP-14539; SYM-1219 |
| AHFS/Drugs.com | International Drug Names |
| License data |
|
| Routes of administration | Oral [1] |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.020.123 |
| Chemical and physical data | |
| Formula | C7H11N3O3 |
| Molar mass | 185.183 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Secnidazole (trade names Flagentyl, Sindose, Secnil, Solosec) is a nitroimidazole anti-infective used to treat bacterial vaginosis and trichomoniasis. [2] [1] It is taken orally. [1]
Structurally it actually methyl-metronidazole. Effectiveness in the treatment of dientamoebiasis has been reported. [3] It has also been tested against Atopobium vaginae . [4]
In the United States, secnidazole is FDA-approved for the treatment of bacterial vaginosis and trichomoniasis in adult women. [2] [5] It was approved in the United States in 2017. [1]